Australia's Telix Pharmaceuticals rises on positive outlook for innovative drugs

Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.6% to A$12.25, marking their strongest trading session since December 11

Stock hits its highest level since December 17

Biopharmaceutical co received positive results from Phase 3 registration study of Illuccix, sees submission of new drug application (NDA) for the same in China

Says NDA for Pixclara to U.S. FDA is "progressing well"

Also believes co has reached alignment with FDA on remediation of identified deficiencies regarding Zircaix's chemistry, manufacturing, and controls package

Stock down 51.2% YTD, including the day's moves